Agomab Reports Positive Phase 2a Results for Ontunisertib in Fibrostenosing Crohn’s Disease

FDA Expands RINVOQ® Indication for Inflammatory Bowel Disease

AstraZeneca Partners with Immunai in $85M AI-Driven IBD Deal

Phase 4 Study: Vedolizumab More Effective in Early Crohn’s Disease

CU Anschutz Study Links MAIT Cells to Gut Inflammation

SMC Approves TREMFYA® for Crohn’s Disease and Ulcerative Colitis

MRC Researchers Uncover Cell Mechanism Behind Crohn’s Fistulas

Numab and Kaken Partner on First-in-Class Multispecific Antibody for IBD

Rose Szabady

Senior Director Ferring International Center SA

Wednesday 1st April 2026

Precision Targeting of IL-6 Trans-Signaling: Restoring Balance Between Inflammation & Regeneration

11:30 am

Present quantitative modeling insights predicting that selective trans-signaling inhibition will permit faster tissue healing than global IL-6 blockade
Discuss translational strategies to validate these findings through biomarkers, imaging modalities, and early proof-of-concept trials
Highlight implications for trial design, including precision endpoints, patient stratification, and integrating modeling into clinical decision making